The imperative for increased investment for an HIV cure

Remko van Leeuwen¹, Françoise Barré-Sinoussi², Michaela Müller-Trutwin³, Asier Sáez-Cirión², Monique Nijhuis⁴, Sharon R Lewin⁵, Thumbi Ndung'u⁶, Florence Riako-Anam⁷, Mitchell Warren⁸, Izukanji Sikazwe⁹, Birgit Poniatowski¹⁰, Beatriz Grinsztejn¹¹, Cissy Kityo¹², Masen Davis¹³, Ole S Søgaard¹⁴, Marcus Altfeld¹⁵, Javier Martinez-Picado¹⁶, Linos Vandekerckhove¹⁷, Andrea Gramatica¹⁸, Devin Sok¹⁹, Simon Collins²⁰, Yazdan Yazdanpanah²¹

Affiliations

¹ Aidsfonds-Soa Aids Nederland, 1014 AX Amsterdam, Netherlands. Electronic address: rvanleeuwen@soaaids.nl.
² Sidaction, Paris, France; Institut Pasteur, Université Paris Cité, Paris, France.
³ Institut Pasteur, Université Paris Cité, Paris, France.
⁴ University Medical Centre Utrecht, Spiral Research Consortium, Utrecht, Netherlands; HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
⁵ Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection, Melbourne, VIC, Australia.
⁶ Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General, Massachusetts Institute of Technology and Harvard University, Boston, MA, USA; Division of Infection and Immunity, University College London, London UK.
⁷ Global Network of People living with HIV, Johannesburg, South Africa.
⁸ AIDS Vaccine Advocacy Coalition, New York, NY, USA.
⁹ Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; Africa HIV Cure Consortium, Lusaka, Zambia.
¹⁰ International Aids Society, Geneva, Switzerland.
¹¹ International Aids Society, Geneva, Switzerland; FIOCRUZ HIV/AIDS Service, Rio de Janeiro, Brazil.
¹² Joint Clinical Research Centre, Kampala, Uganda.
¹³ Funders Concerned About AIDS, Washington, DC, USA.
¹⁴ Aarhus University Hospital, Aarhus, Denmark.
¹⁵ German Centre for Infectious Diseases Research, Leipzig, Germany; Leibniz-Institute of Virology, Leipzig, Germany.
¹⁶ IrsiCaixa, Barcelona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain; Catalan Institution for Research and Advanced Studies, Barcelona, Spain.
¹⁷ Department of General Internal Medicine in the Ghent University Hospital, Ghent, Belgium.
¹⁸ amfAR, New York, NY, USA.
¹⁹ Global Health Investment Corporation, New York, NY, USA.
²⁰ European AIDS Treatment Group, Brussels, Belgium; HIV i-Base, London, UK.
²¹ ANRS Emerging Infectious Diseases, Paris, France.

PMID: 40712628
DOI: 10.1016/S2352-3018(25)00193-6

The imperative for increased investment for an HIV cure

Remko van Leeuwen et al. Lancet HIV. 2025.

. 2025 Jul 22:S2352-3018(25)00193-6.

doi: 10.1016/S2352-3018(25)00193-6. Online ahead of print.

Authors

Affiliations

¹ Aidsfonds-Soa Aids Nederland, 1014 AX Amsterdam, Netherlands. Electronic address: rvanleeuwen@soaaids.nl.
² Sidaction, Paris, France; Institut Pasteur, Université Paris Cité, Paris, France.
³ Institut Pasteur, Université Paris Cité, Paris, France.
⁴ University Medical Centre Utrecht, Spiral Research Consortium, Utrecht, Netherlands; HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
⁵ Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection, Melbourne, VIC, Australia.
⁶ Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General, Massachusetts Institute of Technology and Harvard University, Boston, MA, USA; Division of Infection and Immunity, University College London, London UK.
⁷ Global Network of People living with HIV, Johannesburg, South Africa.
⁸ AIDS Vaccine Advocacy Coalition, New York, NY, USA.
⁹ Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; Africa HIV Cure Consortium, Lusaka, Zambia.
¹⁰ International Aids Society, Geneva, Switzerland.
¹¹ International Aids Society, Geneva, Switzerland; FIOCRUZ HIV/AIDS Service, Rio de Janeiro, Brazil.
¹² Joint Clinical Research Centre, Kampala, Uganda.
¹³ Funders Concerned About AIDS, Washington, DC, USA.
¹⁴ Aarhus University Hospital, Aarhus, Denmark.
¹⁵ German Centre for Infectious Diseases Research, Leipzig, Germany; Leibniz-Institute of Virology, Leipzig, Germany.
¹⁶ IrsiCaixa, Barcelona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain; Catalan Institution for Research and Advanced Studies, Barcelona, Spain.
¹⁷ Department of General Internal Medicine in the Ghent University Hospital, Ghent, Belgium.
¹⁸ amfAR, New York, NY, USA.
¹⁹ Global Health Investment Corporation, New York, NY, USA.
²⁰ European AIDS Treatment Group, Brussels, Belgium; HIV i-Base, London, UK.
²¹ ANRS Emerging Infectious Diseases, Paris, France.

PMID: 40712628
DOI: 10.1016/S2352-3018(25)00193-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

SRL has received investigator-initiated grant funding from Gilead, Merck, and ViiV Healthcare, and has been a paid member of advisory boards to Abbvie, Gilead, Immunocore, and Esfam. JM-P declares institutional grants from Merck Sharp and Dohme, ViiV Healthcare, and Grifols. MD declares grants from Gilead Sciences, ViiV Healthcare, and Merck Sharp and Dohme, and is advisory board member of ILGA-Europe and Council for Global Equality. OSS declares participation in scientific advisory boards for Immunocore, ViiV Healthcare, Merck Sharp and Dohme, Gilead Sciences, and AbbVie, and is (unpaid) board member and treasurer for the Nordic Scoiety for Clinical Microbiology and Infectious Diseases. RvL declares to be inventor of an pending international patent application P137348EP00 for treatment of immune paralysis, is a member of the Advisory Committee on Public Health Emergencies of the European Commission (unpaid) and member of the Joint Industrial Cooperation Forum of the Health Emergency Response Agency of the European Commission, as well as board Member and Vice President of the Biotech companies from Europe innovating in Anti-Microbial resistance research Alliance (unpaid), representing European biotechs on working on antimicrobials, and is a founder and stock holder of biotech company SurvivX, which is working on treatment of immune paralysis. All other authors declare no competing interests.

LinkOut - more resources

Full Text Sources
- ClinicalKey

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The imperative for increased investment for an HIV cure

Affiliations

The imperative for increased investment for an HIV cure

Authors

Affiliations

Conflict of interest statement

LinkOut - more resources

Full Text Sources